Treatment of tuberculosis and optimal dosing schedules

Thorax

Volumn 66, Issue 11, 2011, Pages 997-1007

  Chang, Kwok Chiu ^a   Leung, Chi Chiu ^a   Grosset, Jacques ^b   Yew, Wing Wai ^c  

^a DEPARTMENT OF HEALTH   (Hong Kong)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; CASE CONTROL STUDY; COHORT ANALYSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFECTION CONTROL; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULOSIS;

EID: 80054123332     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.148585     Document Type: Review

References (89)

1. Mitchison DA. The search for new sterilizing anti-tuberculosis drugs. Front Biosci 2004;9:1059-72. (Pubitemid 39060829)
2. National Tuberculosis Institute. Tuberculosis in a rural population of South India: a five-year epidemiological study. Bull World Health Organ 1974;51:473-88.
3. Springett VH. Ten-year results during the introduction of chemotherapy for tuberculosis. Tubercle 1971;52:73-87.
4. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;4:796-806.
5. Zhang Y. Advances in the treatment of tuberculosis. Clin Pharmacol Ther 2007;82:595-600. (Pubitemid 47622532)
6. Fox W. Self-administration of medicaments. A review of published work and a study of the problems. Bull Int Union Tuberc 1962;32:307-31.
7. Dawson JJ, Devadatta S, Fox W, et al. A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS. Bull World Health Organ 1966;34:533-51.
8. Kamat SR, Dawson JJ, Devadatta S, et al. A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull World Health Organ 1966;34:517-32.
9. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:S231-79. (Pubitemid 29481843)
10. World Health Organization. Global Tuberculosis Programme. Global Tuberculosis Control. Geneva, Switzerland: WHO Report, 1997. WHO/GTB/97.225.
11. Kamolratanakul P, Sawert H, Lertmaharit S, et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999;93:552-7. (Pubitemid 29495849)
12. Walley JD, Khan MA, Newell JN, et al. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 2001;357:664-9. (Pubitemid 32206424)
13. Zwarenstein M, Schoeman JH, Vundule C, et al. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998;352:1340-3. (Pubitemid 28510914)
14. Chaulk CP, Moore-Rice K, Rizzo R, et al. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995;274:945-51.
15. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis. We can't afford not to try it. N Engl J Med 1993;328:576-8. (Pubitemid 23053837)
16. Sharma SK, Liu JJ. Progress of DOTS in global tuberculosis control. Lancet 2006;367:951-2.
17. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet 1995;345:1545-8.
18. Chan CY, Au-Yeang C, Yew WW, et al. Postantibiotic effects of antituberculosis agents alone and in combination. Antimicrob Agents Chemother 2001;45:3631-4. (Pubitemid 33107895)
19. Dickinson JM, Mitchison DA. In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens. Tubercle 1968;49(Suppl):66-70.
20. Frieden T. What is the intermittent treatment and what is the scientific basis for intermittency? In: Frieden T, ed. Toman's Tuberculosis. Case Detection Treatment, and Monitoring-Questions and Answers. 2nd edn. Geneva: World Health Organization, 2004:130-8.
21. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-8. (Pubitemid 350057771)
22. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979;76:771-81.
23. Grumbach F, Canetti G, Grosset J, et al. Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model. Tubercle 1967;48:11-26.
24. Lotte A, Hatton F, Perdrizet S, et al. A concurrent comparison of intermittent (twice-weekly) isoniazid plus streptomycin and daily isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis; tuberculosis chemotherapy centre, Madras. Bull World Health Organ 1964;31:247-71.
25. Cao JP, Zhang LY, Zhu JQ, et al. Two-year follow-up of directly-observed intermittent regimens for smear-positive pulmonary tuberculosis in China. Int J Tuberc Lung Dis 1998;2:360-4. (Pubitemid 28239856)
26. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996;154:1034-8.
27. Zhanel GG, Hoban DJ, Harding GK. The postantibiotic effect: a review of in vitro and in vivo data. DICP 1991;25:153-63.
28. Frieden T, ed. Toman's Tuberculosis. Case Detection Treatment, and Monitoring - Questions and Answers. 2nd edn. Geneva: World Health Organization, 2004.
29. Scottish Intercollegiate Guidelines Network. SIGN 50: A Guideline Developer's Handbook. Edinburgh: SIGN:2008.
30. Anon. Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy. Int J Tuberc Lung Dis 2001;5:40-5.
31. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010;50:1288-99.
32. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007;175:1199-206. (Pubitemid 46855463)
33. Li J, Munsiff SS, Driver CR, et al. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis 2005;41:83-91. (Pubitemid 40863749)
34. Chang KC, Leung CC, Yew WW, et al. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004;170:1124-30. (Pubitemid 39488627)
35. Chang KC, Leung CC, Yew WW, et al. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:1153-8. (Pubitemid 44772087)
36. Gao X, Li J, Yang Z, et al. Rifapentine vs rifampicin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2009;13:810-19.
37. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for tuberculosis. Cochrane Database Syst Rev 2000:CD000970.
38. Mwandumba HC, Squire SB. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database Syst Rev 2001:CD000970.
39. Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 2008;336:484-7. (Pubitemid 351350598)
40. Ziganshina LE, Garner P. Tuberculosis (HIV-negative people). Clin Evid (Online) 2009;4:904.
41. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009;6:e1000146.
42. Prasad R, Garg R, Mukerji P, et al. Comparative study of daily and thrice weekly intermittent regimens given for six months in the treatment of pulmonary tuberculosis. J Intern Med India 2001;4:1-3. (Pubitemid 32372839)
43. Alvarez TA, Rodrigues MP, Viegas CA. Prevalence of drug-resistant mycobacterium tuberculosis in patients under intermittent or daily treatment. J Bras Pneumol 2009;35:555-60.
44. Paramasivan CN, Chandrasekaran V, Santha T, et al. Bacteriological investigations for short-course chemotherapy under the tuberculosis programme in two districts of India. Tuberc Lung Dis 1993;74:23-7. (Pubitemid 23080931)
45. Singla R, Srinath D, Gupta S, et al. Risk factors for new pulmonary tuberculosis patients failing treatment under the revised National Tuberculosis Control Programme, India. Int J Tuberc Lung Dis 2009;13:521-6.
46. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009;6:e1000150.
47. Escalante P, Graviss EA, Griffith DE, et al. Treatment of isoniazid-resistant tuberculosis in southeastern Texas. Chest 2001;119:1730-6. (Pubitemid 32744929)
48. Menon PR, Lodha R, Sivanandan S, et al. Intermittent or daily short course chemotherapy for tuberculosis in children: meta-analysis of randomized controlled trials. Indian Pediatr 2010;47:67-73.
49. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47:2118-24. (Pubitemid 36753560)
50. Gumbo T, Dona CSWS, Meek C, et al. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009;53:3197-204.
51. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005;40:1481-91. (Pubitemid 40628637)
52. Rosenthal IM, Zhang M, Almeida D, et al. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008;178:989-93.
53. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
54. Rosenthal IM, Williams K, Tyagi S, et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 2006;174:94-101. (Pubitemid 43955249)
55. Veziris N, Lounis N, Chauffour A, et al. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Antimicrob Agents Chemother 2005;49:4015-19. (Pubitemid 41400940)
56. Daniel N, Lounis N, Ji B, et al. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. Am J Respir Crit Care Med 2000;161:1572-7. (Pubitemid 30329030)
57. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003;167:1341-7. (Pubitemid 36609717)
58. Goutelle S, Bourguignon L, Maire PH, et al. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009;53:2974-81.
59. Gupta P, Roy V, Sethi GR, et al. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses. Br J Clin Pharmacol 2008;65:423-7. (Pubitemid 351316921)
60. Jayaram R, Shandil RK, Gaonkar S, et al. Isoniazid pharmacokinetics- pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004;48:2951-7. (Pubitemid 38989160)
61. Budha NR, Lee RB, Hurdle JG, et al. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinb) 2009;89:378-85.
62. Hong Kong Chest Service/British Medical Research Council. Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981;1:171-4.
63. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council. Tubercle 1982;63:89-98.
64. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-34.
65. Zierski M, Bek E, Long MW, et al. Short-course (6-month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis 1980;122:879-89. (Pubitemid 11207865)
66. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004;364:1244-51. (Pubitemid 39311345)
67. Anon. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils. Lancet 1978;2:334-8.
68. Anon. Controlled clinical trial of 4 short-couse regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tubercle 1983;64:153-66.
69. Anon. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study. Tubercle 1986;67:5-15.
70. Crofton J, Douglas E. Respiratory Diseases. 2nd edn. Oxford: Blackwell Scientific, 1975.
71. East African/British Medical Research Councils. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. Lancet 1973;1:1331-8.
72. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423-30. (Pubitemid 16126276)
73. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998;2:10-5. (Pubitemid 28108937)
74. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-27.
75. Mitchison DA. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2003;167:1298-9. (Pubitemid 36609707)
76. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis 1988;137:1217-22.
77. Acocella G, Pagani V, Marchetti M, et al. Kinetic studies on rifampicin. I. Serum concentration analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy 1971;16:356-70.
78. Binda G, Domenichini E, Gottardi A, et al. Rifampicin, a general review. Arzneimittelforschung 1971;21:1907-77.
79. East African/British Medical Research Council Pyrazinamide Investigation. A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969;50:81-114.
80. Hong YP, Kim SC, Chang SC, et al. Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions. Tubercle 1988;69:241-53. (Pubitemid 19009801)
81. Dickinson JM, Mitchison DA, Lee SK, et al. Serum rifampicin concentration related to dose size and to the incidence of the 'flu' syndrome during intermittent rifampicin administration. J Antimicrob Chemother 1977;3:445-52. (Pubitemid 8186493)
82. Girling DJ. Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Clinical observations on adverse reactions. Scand J Respir Dis Suppl 1973;84:119-24.
83. Peloquin C. What is the 'right' dose of rifampin? Int J Tuberc Lung Dis 2003;7:3-5. (Pubitemid 36427025)
84. Ramakrishnan CV, Janardhanam B, Krishnamurthy DV, et al. Toxicity of pyrazinamide, administered once weekly in high dosage, in tuberculous patients. Bull World Health Organ 1968;39:775-9.
85. Kamal N, Mukerjee PK, Kishore K, et al. Liver functions during pyrazinamide therapy. Indian J Tuberc 1976;23:14-18.
86. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003;7:6-21. (Pubitemid 36427026)
87. Burman WJ. The hunt for the elusive surrogate marker of sterilizing activity in tuberculosis treatment. Am J Respir Crit Care Med 2003;167:1299-301. (Pubitemid 36609708)
88. Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 2010;10:387-94.
89. Golub JE, Durovni B, King BS, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008;22:2527-33.